Year All2026202520242023202220212020201920182017201620152014 Mar 04, 2020 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results Jan 06, 2020 Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome Nov 13, 2019 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results Oct 25, 2019 Soleno Therapeutics Announces Closing of $15.4 Million Public Offering of Common Stock Oct 23, 2019 Soleno Therapeutics Announces Pricing of $13.4 Million Public Offering of Common Stock Oct 22, 2019 Soleno Therapeutics Announces Proposed Public Offering of Common Stock Oct 02, 2019 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome Sep 24, 2019 Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome Sep 19, 2019 Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies Aug 07, 2019 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results
Mar 04, 2020 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
Jan 06, 2020 Soleno Therapeutics Completes Target Enrollment in Ongoing DESTINY PWS Phase III Trial of DCCR in Prader Willi Syndrome
Nov 13, 2019 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2019 Financial Results
Oct 02, 2019 Soleno Therapeutics Announces Positive Outcome from Second Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome
Sep 24, 2019 Soleno Therapeutics Announces Publication of Results from Previously Completed Phase II Trial of DCCR for Treatment of Prader-Willi Syndrome
Sep 19, 2019 Soleno Therapeutics to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Disease Companies
Aug 07, 2019 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2019 Financial Results